Please contact the FOxTROT Study Office if you have queries relating to the trial:


                              Tel:  0121 415 9105     Fax: 0121 415 8871

Those which are commonly asked will include be added to this page in due course, so please check here in the future even if you have not found the answer you were after on this visit.

What do I do if I am interested in participating in FOxTROT?

If you would like to participate in the FOxTROT Trial then please download and complete the Site Registration Form and send it back to the FOxTROT Trial office.

Alternatively for further infromation contact the FOxTROT Trial office


Tel:      0121 415 9105

Fax:     0121 415 8871

How do I randomise a patient into the FOxTROT Trial?

To randomise a patient into the FOxTROT Trial Please call the randomisation line on:

                  Tel: 0800953 0274 (toll free in the uk) or +44 (0)121 415 9137

Telephone randomisation is avaliable Monday-Friday 0900-1700 UK time

Randomisation notepads should be used to collate the necessary information and be completed prior to randomisation.

Click here to download a copy of the FOxTROT Randomisation Notepad

Can the chemotherapy regimen be changed whilst the patient is on the trial?

Crossover from one chemotherapy regimen to the other is not recommended and it is only permitted within the FOxTROT protocol if there is a compelling clinical reason to do so.  Please always discuss any changes to the allocated regimen with the trials team.

When do I need to take the translational blood sample, and how do I send it?

The translational blood sample should be taken after consent and prior to the first treatment (surgery or chemotherapy, whichever comes first). Once taken, the blood sample should be sent to the FOxTROT lab at ST James' University Hospital in Leeds as detailed on page 13 of the protocol.

Please note that we only provide safe boxes. Needles, blood tubes, etc. are not provided by the trial office and are to be used from hospital stock. Please contact the FOxTROT trial office if the blood sample has been missed.

Where do we send the biopsy block for RAS screening?

There are two testing laboratories for RAS testing: St James’ University Hospital in Leeds and the Queen Elizabeth Hospital in Birmingham. Please send the block to whichever lab is closer to you. If you are unsure please contact the trial office.

The addresses of the two main laboratories are:

Dr Susan Richman, FOxTROT Trial Laboratory, Leeds Institute of Molecular Medicine, Section of Pathology and Tumour Biology, Wellcome Trust Brenner Building, St James' University Hospital, Leeds LS9 7TF

Dr Philippe Taniere, Consultant Pathologist, Department of Cellular Histopathology, Level -1, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham B15 2WB

Please do not send the biopsy block to the FOxTROT Trial Office at the University of Birmingham.  To do so would cause unnecessary delays as the block will need to be sent on to one of the two testing laboratories.

How long will it take for the RAS biopsy result to become available?
Do we need this result before we can enter the patient into the trial?

The RAS result takes on average 7 days from receipt at the testing laboratory.  Please be sure to take this into account when arranging the potential start date of treatment.

You do not need to wait for the result in order to randomise a patient into the trial as the first instance of randomisation is used only to establish the patient's trial number and treatment duration.  Panitumumab allocation will be confirmed via email when the RAS result is received and entered by a member of the FOxTROT team.

How long are patients followed up for?

Whilst the primary end point for the trial is disease free survival at two years, there is no specific end to follow up for FOxTROT and patients should be followed up annually until the trial is complete.  Please refer to page 15 of the trial protocol for more information.

Do we need to arrange a colonoscopy at the 2 year time point?

A colonoscopy is required at 2 years if a full bowel examination was not performed prior to surgery.  

One of my patients has had their chemotherapy stopped. What happens now?

Please inform the trials office of why chemo has been stopped, when it was stopped and who made the decision to stop.  

Data from every patient is important, even if the patient did not receive the full planned trial treatment.  Please continue to follow these patients up as per protocol: the only change to original schedule is the omission of chemotherapy. 

Who can take consent to FOxTROT?

Trial entry consent must be taken by an oncologist or surgeon, who has been appropriately delegated the role of obtaining informed consent, and for whom we are in receipt of a signed CV and GCP certificate dated within the last 3 years.  

RAS screening consent can be taken by an appropriately trained research nurse, as delegated by the local Principal Investigator.

How do I report a patient withdrawal?

There is no specific form to confirm patient withdrawal from FOxTROT. Please alert the FOxTROT Trial Office and we will record accordingly. Patients can withdraw from FOxTROT trial in different ways:

• Withdrawal from trial-specific treatment: The patient will not complete treatment as per the FOxTROT protocol. Follow-up according to the protocol would still be requested.

• Withdrawal from trial-specific follow-up: The patient has had trial treatment but does not wish to be followed up according to the protocol. The patient will be followed up according to standard practice. It must be confirmed that the patient has agreed that follow-up data collected at standard clinic visits may be used in the final analysis. Patients should be asked if data held by central registries at The Health and Social Care Information Centre can still be collected for the study.

Complete withdrawal: The patient is not willing to be followed up for trial purposes at any further visits, i.e. only data collected prior to the withdrawal of consent can be used in the final analysis.

I have a potential patient whose CT scan was performed over a month ago. Are they still eligible?

Randomisation should be within 1 month of the date of CT scan.  If the date of randomisation is outside this period, but the patient is otherwise eligible, please contact the FOxTROT Trial Office.

When should treatment start?

If a patient has been allocated pre-operative chemotherapy, we expect the first cycle of chemotherapy to begin within 2 weeks of randomisation. Surgery should then be performed between 52 and 69 days after the commencement of chemotherapy.

If a patient has been allocated post-operative chemotherapy only, surgery should be arranged as soon as possible as per standard practice.

Post-operative chemotherapy should begin between 4 and 8 weeks after surgery.